Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Correction to: VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.

Holding AN, Giorgi FM, Donnelly A, Cullen AE, Nagarajan S, Selth LA, Markowetz F.

Genome Biol. 2019 Jun 14;20(1):122. doi: 10.1186/s13059-019-1733-0.

2.

VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.

Holding AN, Giorgi FM, Donnelly A, Cullen AE, Nagarajan S, Selth LA, Markowetz F.

Genome Biol. 2019 May 13;20(1):91. doi: 10.1186/s13059-019-1698-z. Erratum in: Genome Biol. 2019 Jun 14;20(1):122.

3.

Interplay between the androgen receptor signalling axis and microRNAs in prostate cancer.

Fernandes R, Hickey T, Tilley WD, Selth LA.

Endocr Relat Cancer. 2019 Feb 1. pii: ERC-18-0571.R1. doi: 10.1530/ERC-18-0571. [Epub ahead of print] Review.

PMID:
30817318
4.

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.

Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA.

Sci Transl Med. 2019 Feb 6;11(478). pii: eaau5758. doi: 10.1126/scitranslmed.aau5758.

PMID:
30728288
5.

Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

MacFawn I, Wilson H, Selth LA, Leighton I, Serebriiskii I, Bleackley RC, Elzamzamy O, Farris J, Pifer PM, Richer J, Frisch SM.

Mol Immunol. 2019 Jan;105:137-149. doi: 10.1016/j.molimm.2018.11.006. Epub 2018 Nov 30.

PMID:
30508726
6.

Long non-coding RNAs in prostate cancer: Biological and clinical implications.

Das R, Feng FY, Selth LA.

Mol Cell Endocrinol. 2019 Jan 15;480:142-152. doi: 10.1016/j.mce.2018.10.023. Epub 2018 Nov 2. Review.

PMID:
30391670
7.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.

8.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
9.

miR-200/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking.

Pillman KA, Phillips CA, Roslan S, Toubia J, Dredge BK, Bert AG, Lumb R, Neumann DP, Li X, Conn SJ, Liu D, Bracken CP, Lawrence DM, Stylianou N, Schreiber AW, Tilley WD, Hollier BG, Khew-Goodall Y, Selth LA, Goodall GJ, Gregory PA.

EMBO J. 2018 Jul 2;37(13). pii: e99016. doi: 10.15252/embj.201899016. Epub 2018 Jun 5.

10.

A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer.

Matin F, Jeet V, Moya L, Selth LA, Chambers S; Australian Prostate Cancer BioResource, Clements JA, Batra J.

Sci Rep. 2018 Apr 27;8(1):6653. doi: 10.1038/s41598-018-24424-w.

11.

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Centenera MM, Selth LA, Ebrahimie E, Butler LM, Tilley WD.

Cold Spring Harb Perspect Med. 2018 Dec 3;8(12). pii: a030478. doi: 10.1101/cshperspect.a030478. Review.

PMID:
29530945
12.

Data Mining of Small RNA-Seq Suggests an Association Between Prostate Cancer and Altered Abundance of 5' Transfer RNA Halves in Seminal Fluid and Prostatic Tissues.

Dhahbi JM, Atamna H, Selth LA.

Biomark Cancer. 2018 Feb 20;10:1179299X18759545. doi: 10.1177/1179299X18759545. eCollection 2018.

13.

Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.

Armstrong HK, Gillis JL, Johnson IRD, Nassar ZD, Moldovan M, Levrier C, Sadowski MC, Chin MY, Tomlinson Guns ES, Tarulli G, Lynn DJ, Brooks DA, Selth LA, Centenera MM, Butler LM.

Sci Rep. 2018 Feb 1;8(1):2090. doi: 10.1038/s41598-018-19871-4.

14.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

15.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R.

Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.

16.

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.

Pedraza-Arévalo S, Hormaechea-Agulla D, Gómez-Gómez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM.

Prostate. 2017 Nov;77(15):1499-1511. doi: 10.1002/pros.23426. Epub 2017 Sep 14.

PMID:
28905400
17.

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.

Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, Fernandes R, Hanson AR, Denis I, Carroll JS, Dehm SM, Raj GV, Plymate SR, Tilley WD, Selth LA.

Cancer Res. 2017 Jul 1;77(13):3417-3430. doi: 10.1158/0008-5472.CAN-16-1616. Epub 2017 May 4.

18.

MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4.

Wang Q, Selth LA, Callen DF.

Oncotarget. 2017 May 2;8(18):29914-29924. doi: 10.18632/oncotarget.15530.

19.

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer.

Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA, Raj GV.

Cancer Res. 2017 Jun 1;77(11):3101-3112. doi: 10.1158/0008-5472.CAN-16-2169. Epub 2017 Mar 16.

20.

Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality.

Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG.

Oncogene. 2017 Jun 15;36(24):3417-3427. doi: 10.1038/onc.2016.482. Epub 2017 Jan 16.

21.

MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2.

Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA.

Cancer Res. 2017 Feb 15;77(4):1021-1034. doi: 10.1158/0008-5472.CAN-16-2529. Epub 2016 Dec 23.

22.

Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.

Coutinho I, Day TK, Tilley WD, Selth LA.

Endocr Relat Cancer. 2016 Dec;23(12):T179-T197. Epub 2016 Oct 31. Review.

PMID:
27799360
23.

A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.

Armstrong HK, Koay YC, Irani S, Das R, Nassar ZD; Australian Prostate Cancer BioResource, Selth LA, Centenera MM, McAlpine SR, Butler LM.

Prostate. 2016 Dec;76(16):1546-1559. doi: 10.1002/pros.23239. Epub 2016 Aug 16.

PMID:
27526951
24.

Cell-lineage specificity and role of AP-1 in the prostate fibroblast androgen receptor cistrome.

Leach DA, Panagopoulos V, Nash C, Bevan C, Thomson AA, Selth LA, Buchanan G.

Mol Cell Endocrinol. 2017 Jan 5;439:261-272. doi: 10.1016/j.mce.2016.09.010. Epub 2016 Sep 12.

25.

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

Hu DG, Selth LA, Tarulli GA, Meech R, Wijayakumara D, Chanawong A, Russell R, Caldas C, Robinson JL, Carroll JS, Tilley WD, Mackenzie PI, Hickey TE.

Cancer Res. 2016 Oct 1;76(19):5881-5893. Epub 2016 Aug 5.

26.

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.

PMID:
27270433
27.

Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.

Carter SL, Centenera MM, Tilley WD, Selth LA, Butler LM.

BMC Cancer. 2016 Mar 3;16:177. doi: 10.1186/s12885-016-2215-3. No abstract available.

29.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

30.

Expression of androgen receptor splice variants in clinical breast cancers.

Hickey TE, Irvine CM, Dvinge H, Tarulli GA, Hanson AR, Ryan NK, Pickering MA, Birrell SN, Hu DG, Mackenzie PI, Russell R, Caldas C, Raj GV, Dehm SM, Plymate SR, Bradley RK, Tilley WD, Selth LA.

Oncotarget. 2015 Dec 29;6(42):44728-44. doi: 10.18632/oncotarget.6296.

31.

The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype.

Need EF, Selth LA, Trotta AP, Leach DA, Giorgio L, O'Loughlin MA, Smith E, Gill PG, Ingman WV, Graham JD, Buchanan G.

BMC Cancer. 2015 Oct 24;15:791. doi: 10.1186/s12885-015-1819-3.

32.

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, Bradner JE, Raj GV, Tilley WD, Dehm SM.

Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.

33.

Seminal fluid: a useful source of prostate cancer biomarkers?

Roberts MJ, Richards RS, Gardiner RA, Selth LA.

Biomark Med. 2015;9(2):77-80. doi: 10.2217/bmm.14.110. No abstract available.

34.

A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer.

Stegeman S, Moya L, Selth LA, Spurdle AB, Clements JA, Batra J.

Endocr Relat Cancer. 2015 Apr;22(2):265-76. doi: 10.1530/ERC-15-0013. Epub 2015 Feb 10.

PMID:
25670033
35.

Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.

Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, Yaxley J, Lavin MF, Gardiner RA.

Prostate. 2015 Apr 1;75(5):539-49. doi: 10.1002/pros.22942. Epub 2015 Jan 18.

PMID:
25597828
36.

Epithelial plasticity in prostate cancer: principles and clinical perspectives.

Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA.

Trends Mol Med. 2014 Nov;20(11):643-51. doi: 10.1016/j.molmed.2014.09.004. Epub 2014 Sep 25. Review.

PMID:
25262538
37.

Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers.

Selth LA, Roberts MJ, Chow CW, Marshall VR, Doi SA, Vincent AD, Butler LM, Lavin MF, Tilley WD, Gardiner RA.

Endocr Relat Cancer. 2014 Aug;21(4):L17-21. doi: 10.1530/ERC-14-0234. Epub 2014 May 23. No abstract available.

PMID:
24859988
38.

Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.

Hu DG, Hickey TE, Irvine C, Wijayakumara DD, Lu L, Tilley WD, Selth LA, Mackenzie PI.

Horm Cancer. 2014 Apr;5(2):61-71. doi: 10.1007/s12672-014-0171-4. Epub 2014 Feb 26.

PMID:
24570075
39.

MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.

Li X, Roslan S, Johnstone CN, Wright JA, Bracken CP, Anderson M, Bert AG, Selth LA, Anderson RL, Goodall GJ, Gregory PA, Khew-Goodall Y.

Oncogene. 2014 Jul 31;33(31):4077-88. doi: 10.1038/onc.2013.370. Epub 2013 Sep 16.

PMID:
24037528
40.

Functional studies of the yeast med5, med15 and med16 mediator tail subunits.

Larsson M, Uvell H, Sandström J, Rydén P, Selth LA, Björklund S.

PLoS One. 2013 Aug 22;8(8):e73137. doi: 10.1371/journal.pone.0073137. eCollection 2013.

41.

Circulating microRNAs predict biochemical recurrence in prostate cancer patients.

Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD.

Br J Cancer. 2013 Aug 6;109(3):641-50. doi: 10.1038/bjc.2013.369. Epub 2013 Jul 11.

42.

Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.

Trotta AP, Need EF, Selth LA, Chopra S, Pinnock CB, Leach DA, Coetzee GA, Butler LM, Tilley WD, Buchanan G.

Int J Cancer. 2013 Dec 15;133(12):2812-23. doi: 10.1002/ijc.28310. Epub 2013 Jul 6.

43.

Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease.

Selth LA, Townley SL, Gillis JL, Tilley WD, Butler LM.

Methods Mol Biol. 2013;1024:235-46. doi: 10.1007/978-1-62703-453-1_19.

PMID:
23719956
44.

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM.

Oncotarget. 2013 May;4(5):691-704.

45.

Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play.

Sapre N, Selth LA.

Prostate Cancer. 2013;2013:539680. doi: 10.1155/2013/539680. Epub 2013 Mar 12.

46.

Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer cells.

Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G.

Mol Endocrinol. 2012 Nov;26(11):1941-52. doi: 10.1210/me.2011-1314. Epub 2012 Sep 28.

47.

Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.

Chiam K, Ryan NK, Ricciardelli C, Day TK, Buchanan G, Ochnik AM, Murti K, Selth LA; Australian Prostate Cancer BioResource, Butler LM, Tilley WD, Bianco-Miotto T.

Prostate. 2013 Jan;73(2):182-93. doi: 10.1002/pros.22554. Epub 2012 Jul 10.

PMID:
22782870
48.

An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.

Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE, Tilley WD.

Endocr Relat Cancer. 2012 Jul 22;19(4):599-613. doi: 10.1530/ERC-12-0065. Print 2012 Aug.

PMID:
22719059
49.

Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client.

Trotta AP, Need EF, Butler LM, Selth LA, O'Loughlin MA, Coetzee GA, Tilley WD, Buchanan G.

J Mol Endocrinol. 2012 Jul 25;49(2):57-68. Print 2012 Oct.

PMID:
22693264
50.

Circulating microRNAs: macro-utility as markers of prostate cancer?

Selth LA, Tilley WD, Butler LM.

Endocr Relat Cancer. 2012 Jun 18;19(4):R99-R113. doi: 10.1530/ERC-12-0010. Print 2012 Aug. Review.

PMID:
22492480

Supplemental Content

Loading ...
Support Center